196 related articles for article (PubMed ID: 30548972)
1. Role of MDM2 309T>G (rs2279744) and I/D (rs3730485) polymorphisms and haplotypes in risk of papillary thyroid carcinoma, tumor stage, tumor size, and early onset of tumor: A case control study.
Maruei-Milan R; Heidari Z; Salimi S
J Cell Physiol; 2019 Aug; 234(8):12934-12940. PubMed ID: 30548972
[TBL] [Abstract][Full Text] [Related]
2. Association of Mouse Double Minute 2 -309T>G Polymorphism with Acute Myeloid Leukemia in an Iranian Population: A Case- Control Study.
Soleymannejad M; Sheikhha MH; Neamatzadeh H
Asian Pac J Cancer Prev; 2019 Oct; 20(10):3037-3041. PubMed ID: 31653152
[TBL] [Abstract][Full Text] [Related]
3. Role of the MDM2 promoter polymorphism (-309T>G) in acute myeloid leukemia development.
Cingeetham A; Vuree S; Jiwatani S; Kagita S; Dunna NR; Meka PB; Gorre M; Annamaneni S; Digumarti R; Sinha S; Satti V
Asian Pac J Cancer Prev; 2015; 16(7):2707-12. PubMed ID: 25854351
[TBL] [Abstract][Full Text] [Related]
4. Interaction between p53 codon 72 and MDM2 309T>G polymorphisms and the risk of hepatocellular carcinoma.
Qiu M; Liu Y; Yu X; Qin L; Bei C; Zeng X; Qiu X; Tang B; He S; Yu H
Tumour Biol; 2016 Mar; 37(3):3863-70. PubMed ID: 26476535
[TBL] [Abstract][Full Text] [Related]
5. The effect of TP53 and P21 gene polymorphisms on papillary thyroid carcinoma susceptibility and clinical/pathological features.
Heidari Z; Harati-Sadegh M; Arian A; Maruei-Milan R; Salimi S
IUBMB Life; 2020 May; 72(5):922-930. PubMed ID: 31895498
[TBL] [Abstract][Full Text] [Related]
6. The effect of CASP3 rs4647610 and rs4647602 polymorphisms on tumour size and cancer stage in papillary thyroid carcinoma.
Heidari Z; Eskandari M; Aryan A; Rostamzad F; Salimi S
Br J Biomed Sci; 2020 Jul; 77(3):129-134. PubMed ID: 32151194
[TBL] [Abstract][Full Text] [Related]
7. Polymorphisms of p53 and MDM2 genes are associated with severe toxicities in patients with non-small cell lung cancer.
Zheng D; Chen Y; Gao C; Wei Y; Cao G; Lu N; Hou Y; Jiang X; Wang J
Cancer Biol Ther; 2014; 15(11):1542-51. PubMed ID: 25482940
[TBL] [Abstract][Full Text] [Related]
8. Murine double minute clone 2,309T/G and 285G/C promoter single nucleotide polymorphism as a risk factor for breast cancer: a Polish experience.
Piotrowski P; Lianeri M; Rubis B; Knuła H; Rybczyńska M; Grodecka-Gazdecka S; Jagodziński PP
Int J Biol Markers; 2012 Jul; 27(2):e105-10. PubMed ID: 22467100
[TBL] [Abstract][Full Text] [Related]
9. Association of AXIN1 rs12921862 C/A and rs1805105 G/A and CTSB rs12898 G/A polymorphisms with papillary thyroid carcinoma: A case-control study.
Saljooghi S; Heidari Z; Saravani M; Rezaei M; Salimi S
J Clin Lab Anal; 2023 Jan; 37(1):e24804. PubMed ID: 36510340
[TBL] [Abstract][Full Text] [Related]
10. Significance of MDM2 and P14 ARF polymorphisms in susceptibility to differentiated thyroid carcinoma.
Zhang F; Xu L; Wei Q; Song X; Sturgis EM; Li G
Surgery; 2013 May; 153(5):711-7. PubMed ID: 23218882
[TBL] [Abstract][Full Text] [Related]
11. Vascular endothelial growth factor G+405C polymorphism may contribute to the risk of developing papillary thyroid carcinoma.
Bingül İ; Vural P; Doğru-Abbasoğlu S; Çil E; Uysal M
J Clin Lab Anal; 2017 Nov; 31(6):. PubMed ID: 27925342
[TBL] [Abstract][Full Text] [Related]
12. [Association of murine double minute 2 and P53 polymorphisms with breast cancer susceptibility].
Wang ML; Xu YX; Qian J; Wang FH
Zhonghua Yu Fang Yi Xue Za Zhi; 2013 Feb; 47(2):124-8. PubMed ID: 23719102
[TBL] [Abstract][Full Text] [Related]
13. Prognostic potential of the MDM2 309T>G polymorphism in stage I lung adenocarcinoma.
Enokida Y; Shimizu K; Atsumi J; Kakegawa S; Takase Y; Kaira K; Yashima H; Araki T; Nakazawa S; Ohtaki Y; Nagashima T; Alexander L; Usui K; Ishikawa T; Hayashizaki Y; Takeyoshi I
Cancer Med; 2016 Aug; 5(8):1791-801. PubMed ID: 27228500
[TBL] [Abstract][Full Text] [Related]
14. Association between Genetic Polymorphisms in microRNA Machinery Genes and Risk of Papillary Thyroid Carcinoma.
Mohammadpour-Gharehbagh A; Heidari Z; Eskandari M; Aryan A; Salimi S
Pathol Oncol Res; 2020 Apr; 26(2):1235-1241. PubMed ID: 31250375
[TBL] [Abstract][Full Text] [Related]
15. Significance of MDM2-309 polymorphisms and induced corresponding plasma MDM2 levels in susceptibility to laryngeal squamous cell carcinoma.
Zhou J; Liu F; Zhang D; Chen B; Li Q; Zhou L; Lu LM; Tao L
DNA Cell Biol; 2014 Feb; 33(2):88-94. PubMed ID: 24325471
[TBL] [Abstract][Full Text] [Related]
16. Association between microRNA polymorphisms and papillary thyroid cancer susceptibility.
Dong G; Zhang R; Xu J; Guo Y
Int J Clin Exp Pathol; 2015; 8(10):13450-7. PubMed ID: 26722556
[TBL] [Abstract][Full Text] [Related]
17. MDM2 T309G has a synergistic effect with P21 ser31arg single nucleotide polymorphisms on the risk of acute myeloid leukemia.
Ebid GT; Sedhom IA; El-Gammal MM; Moneer MM
Asian Pac J Cancer Prev; 2012; 13(9):4315-20. PubMed ID: 23167335
[TBL] [Abstract][Full Text] [Related]
18. MDM2 309T>G polymorphism and risk of lung cancer in a Korean population.
Park SH; Choi JE; Kim EJ; Jang JS; Han HS; Lee WK; Kang YM; Park JY
Lung Cancer; 2006 Oct; 54(1):19-24. PubMed ID: 16876289
[TBL] [Abstract][Full Text] [Related]
19. The effects of the genetic polymorphisms of antioxidant enzymes on susceptibility to papillary thyroid carcinoma.
Salimi S; Harati-Sadegh M; Eskandari M; Heidari Z
IUBMB Life; 2020 May; 72(5):1045-1053. PubMed ID: 32031754
[TBL] [Abstract][Full Text] [Related]
20. Polymorphisms in selected DNA repair genes and cell cycle regulating genes involved in the risk of papillary thyroid carcinoma.
Halkova T; Dvorakova S; Sykorova V; Vaclavikova E; Vcelak J; Vlcek P; Sykorova P; Kodetova D; Betka J; Lastuvka P; Bavor P; Hoch J; Katra R; Bendlova B
Cancer Biomark; 2016 Jun; 17(1):97-106. PubMed ID: 27314298
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
